| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fletcher factor; kallikrein B plasma; Kallikrein B1; Kininogenin; KLK3; KLKB1; PKK; PKKD; Plasma kallikrein light chain; PPK; Prekallikrein; ;Plasma kallikrein |
| WB Predicted band size | Calculated MW: 71 kDa ; Observed MW: 80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human Plasma kallikrein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于KLKB1抗体的假设性参考文献示例，供参考(注：文献信息为模拟，实际引用需核实)：
1. **标题**：*Targeting Plasma Kallikrein with Monoclonal Antibodies for Hereditary Angioedema Therapy*
**作者**：Zuraw, B.L. et al.
**摘要**：研究报道开发了针对KLKB1的单克隆抗体，通过抑制血浆激肽释放酶活性，显著减少遗传性血管性水肿患者的缓激肽生成，为靶向治疗提供了新策略。
2. **标题**：*Role of KLKB1 in Coagulation and Inflammation: Insights from Antibody-Based Inhibition*
**作者**：Schmaier, A.H. et al.
**摘要**：利用KLKB1特异性抗体阻断其功能，揭示了该蛋白在接触激活凝血通路和炎症反应中的双重作用，为血栓性疾病机制研究提供依据。
3. **标题**：*KLKB1 as a Biomarker in Cardiovascular Disease: Validation via Immunoassay*
**作者**：Prisco, N. et al.
**摘要**：通过酶联免疫吸附试验(ELISA)结合KLKB1抗体，发现血浆中KLKB1水平与动脉粥样硬化严重程度呈正相关，提示其作为心血管风险的潜在标志物。
4. **标题**：*Structural Characterization of KLKB1 Using Polyclonal Antibodies for Epitope Mapping*
**作者**：López-Trascasa, M. et al.
**摘要**：通过多克隆抗体识别KLKB1的抗原表位，解析其三维结构关键区域，为开发高特异性抑制剂奠定基础。
建议通过数据库(如PubMed、Web of Science)以“KLKB1 antibody”或“plasma kallikrein inhibitor”为关键词检索最新文献，以获取真实研究数据。
KLKB1 antibodies target the plasma kallikrein enzyme, encoded by the *KLKB1* gene, which plays a critical role in the kallikrein-kinin system (KKS). This serine protease regulates inflammatory responses, blood pressure, coagulation, and fibrinolysis by cleaving kininogens to release vasoactive kinins, such as bradykinin. Dysregulation of KLKB1 activity is implicated in hereditary angioedema (HAE), diabetic complications, hypertension, and thrombosis, making it a therapeutic and diagnostic focus.
KLKB1 antibodies are essential tools for studying the enzyme's expression, localization, and function in physiological and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and ELISA to quantify KLKB1 levels in tissues or biofluids. Therapeutic antibodies or inhibitory peptides targeting KLKB1 are under investigation to block excessive kinin production in HAE or inflammation-driven diseases. Additionally, these antibodies aid in exploring KLKB1's interactions with inhibitors (e.g., C1 esterase inhibitor) or its role in cross-activating coagulation Factor XII.
Most KLKB1 antibodies are produced in rabbits or mice using recombinant KLKB1 protein fragments. Specificity and cross-reactivity validation are crucial due to structural similarities among kallikrein family proteases. Advances in recombinant antibody engineering have improved their clinical applicability, including diagnostics for kallikrein-related disorders and monitoring treatment efficacy in trials targeting the KKS pathway.
×
